ASND
Ascendis Pharma AS
NASDAQ: ASND · HEALTHCARE · BIOTECHNOLOGY
$220.28
-0.81% today
Updated 2026-04-29
Market cap
$13.61B
P/E ratio
—
P/S ratio
18.90x
EPS (TTM)
$-4.40
Dividend yield
—
52W range
$151 – $251
Volume
0.7M
Ascendis Pharma AS (ASND) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-88.4%
Last 4 quarters
Revenue YoY growth
+41.0%
Most recent quarter
EPS YoY growth
+14.1%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.7%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+4.9%
2025-08-07
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-11 | $-0.55 | -266.7% | $224.19 | $218.10 | -2.7% |
| 2025-11-06 | $-1.00 | -257.1% | $197.75 | $197.74 | -0.0% |
| 2025-08-07 | $-0.64 | +51.1% | $182.60 | $191.49 | +4.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.15 | $-0.55 | -266.7% | $245.18M | +41.0% |
| 2025-09-30 | $-0.28 | $-1.00 | -257.1% | $213.63M | +269.4% |
| 2025-06-30 | $-1.31 | $-0.64 | +51.1% | $158.04M | +339.0% |
| 2025-03-31 | $-1.51 | $-1.58 | -4.6% | $100.95M | +5.3% |
| 2024-12-31 | $-0.93 | $-0.64 | +31.2% | $173.92M | +26.3% |
| 2024-09-30 | $-1.49 | $-1.72 | -15.4% | $57.83M | +20.4% |
| 2024-06-30 | $-1.46 | $-2.11 | -44.5% | $36.00M | -24.0% |
| 2024-03-31 | $-1.50 | $-2.30 | -53.3% | $95.89M | — |
| 2023-12-31 | $-2.03 | $-1.54 | +24.1% | $137.70M | — |
| 2023-09-30 | $-2.38 | $-2.88 | -21.0% | $48.03M | — |
| 2023-06-30 | $-2.59 | $-2.16 | +16.6% | $47.39M | — |
Frequently asked questions
Has Ascendis Pharma AS beaten earnings estimates?
Ascendis Pharma AS has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -88.4% over the last 4 quarters.
How does ASND stock react to earnings?
ASND stock has moved an average of +0.7% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Ascendis Pharma AS's revenue growth rate?
Ascendis Pharma AS reported year-over-year revenue growth of +41.0% in its most recent quarter, with EPS growing +14.1% year-over-year.